Chapter: 1726

Rachel settled back in her seat, while Rowell watched the interaction, eventually smiling.

“Klein, please proceed."

Taking Rowell's words as a cue, Klein pushed aside his thoughts and nodded. He rose from his seat, picked up the remote control, and started elaborating on the project's advancements and the latest data.

The meeting commenced and extended for nearly three hours, reaching its conclusion as the sun had already set.

Rachel checked the time on her laptop and then observed Rowell and his team, who were attentively listening to Klein's presentation.

As Klein wrapped up his report, he concluded, “Everyone, that's the end of my presentation. Our project is currently displaying promising potential, and although our team's core operations have moved to Trevinia, its foundation remains in Apliaria. With your support, I'm confident we can excel in this venture."

Rowell directed his attention to the data in his hands.

"You say the prospects are good, but from what we see now, the experimental data isn't convincing. The initial investments haven't shown significant returns. Our support might not make a big difference. To be honest, I hold high expectations for this project, but at present, the data remains inconclusive, and your proposed price isn't particularly competitive."

The lack of clarity in their experimental data was indeed a vulnerability.

This was primarily because the laboratory had not yet been fully established, and medical research projects typically demanded an extensive preparatory phase before producing tangible outcomes.

However, their collaborators were well-informed about this aspect, and they were more focused on the eventual results rather than the interim process.

Presenting the project's current stage wasn't very convincing.

“These are preliminary figures. We're continuously making progress,"

Klein attempted to clarify. He had expected that Rowell might use this as a negotiating point, but for some reason, the well-thought-out words he had prepared seemed to be stuck in his throat.

"Klein, what you're discussing pertains to the future. Who can predict the future with certainty? Moreover, experiments can yield varied results, and factors can change over time. If we hastily make a decision, and the outcomes don't meet our expectations later, it won't just be us who suffer; it will also impact you. We've examined the price you've proposed and conducted our research. We find it somewhat unreasonable." Rowell, an experienced player in the corporate arena, detected Klein's brief hesitation and capitalized on the opportunity.

"We..."

Rowell closed the materials.

"How about you go back and discuss it further? Come up with a new price list for us. This way, it will be easier for us to proceed."

Shayla and Barnett looked at each other, their anxiety palpable.

They relied on the Health Bureau's support to secure the project permit and advance their efforts. If this phase encountered delays, the project would remain stuck.

This point was not meant to be their final objective.

As the Health Bureau representatives began packing up to leave, Klein appeared speechless.

Just as Rowell was getting ready to leave, Rachel stood up.

"Mr. Newman, I agree with you. Our experimental data isn't overly convincing, and our pricing might be a bit steep."